Tue, Jul 22, 2014, 8:09 AM EDT - U.S. Markets open in 1 hr 21 mins

Recent

% | $
Click the to save as a favorite.

Vical Incorporated Message Board

  • nailp68 nailp68 Dec 13, 2005 6:26 PM Flag

    ex broker

    you still around what is your take on the action and timeline for any positive news

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Same BS. Every three months. Same old crap.

      VJ this and VJ that.

      Face it.....I am in control!!!

      I call the shots and I do what I want!!!!

      No one can stop me from becoming filthy rich.

      You guys are just a bunch of little peons....you not worth more than the snot hanging from my nose.

      It is so DAMN GREAT to BE THE KING!!!

      I LOVE MYSELF!!!!

    • Not likely. He is well entrenched, quite secure, and plays hardball. Not exactly Mr. nice guy- I can attest from personal experience.

      Very smooth- "unctuous" is one word that comes to mind. Worth looking up. And getting quite old now.

      But yes, that is the spring from which flows all of the other issues IMO. VJ was quite explict to me a few years ago- Gordon offered him various opportunities, and he selected the Vical CEO slot from that menu of options.

      As the man said, the license plate says Merck, and MRK corporate culture played out on a small scale is exactly what has been implemented.

      I am unaware of anything productive that has come out of any of these newcos (for and not for profit) where he has been in control. A testament to the corrosive effects of cronyism, IMO.

      This summary from the Aeras web site.
      http://www.aeras.org/about/board/index.html

      R. Gordon Douglas, Jr., MD, Chairman
      R. Gordon Douglas, Jr. currently serves as consultant to the Vaccine Research Center at the National Institutes of Health. He is director of the following biotech companies: Advancis Pharmaceuticals, Elusys Therapeutics, Vical (chairman), VaxInnate, Iomai Previously, Dr. Douglas held the position of President, Merck Vaccines, responsible for research, development, manufacturing and marketing of Merck Vaccines� vaccine products from 1990 until 1999. From 1982 to 1990 he was Professor of Medicine and Chairman, Department of Medicine, Cornell University Medical College and Physician-in-Chief of the New York Hospital Previously he was head of the infectious disease unit at the University of Rochester School of Medicine. He is author of over 200 scientific publications and was co-editor with Mandell and Bennett of Principles and Practice of Infectious Diseases for the first three editions. He is a member of the Institute of Medicine, the Association of American Physicians, and the American Society of Clinical Investigation. Dr. Douglas is a graduate of Princeton University and Cornell University School of Medicine.

    • Hey nailp68,

      Yes , I'm still here. Will comment more later.

      Good luck to you.

      EB.

      • 1 Reply to exbroker56
      • Well if A-7 doesn't come through the only thing management has been able in 6 years is to advance one drug into phase II (cmv).That is pretty sad. No it is more than sad. Now I believe their tech is being used many and will be a big hit. This has nothing to do with management.

        I met with VJ last April, he made direct statements, that I have notes on, that are now lies. I held my position because of what he said.He knows who I am and if he wants to debate the facts with me I would be glad to.
        I sold most of my position recently. Again I do believe what Johno,abcde,berries and other have said will come to pass. I don't blame Alan in IR, he can only say what he is told, but VJ, and our board have not done well by shareholders.

        EB.

 
VICL
1.31+0.02(+1.55%)Jul 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.